title: [Clinical aspects and treatment of primary focal segmental glomerulosclerosis and hyalinosis].
abstract: The authors studied the clinico-laboratory values and efficacy of pathogenetic treatment in 8 patients with primary segmental glomerulosclerosis and hyalinosis (PSGH). The disease is characterized by distinct disorders in the T-system immunity. Glucocorticoid treatment did not essentially effect the course of PSGH. Cyclophosphane treatment allowed to achieve essential stable clinical improvement in certain patients.
authors.forename: A I
authors.initials: AI
authors.lastname: Diadyk
authors.forename: I V
authors.initials: IV
authors.lastname: Vasilenko
authors.forename: N I
authors.initials: NI
authors.lastname: Shpilevaia
authors.forename: O V
authors.initials: OV
authors.lastname: Siniachenko
authors.forename: V G
authors.initials: VG
authors.lastname: Kobets
mesh_terms: D000293:Adolescent; D000328:Adult; D001707:Biopsy, Needle; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000175:diagnosis*; D005923:Glomerulosclerosis, Focal Segmental / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007668:Kidney / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D011239:Prednisolone / Q000627:therapeutic use
chemical_list: D003520:Cyclophosphamide; D011239:Prednisolone
vernacular_title: Klinika i lechenie pervichnogo fokal'nogo segmentarnogo glomeruloskleroza i gialinoza.